Sign in
CompletedNo phase

PHOTOFINISH: a Clinical Study To Evaluate The Efficacy And Safety Of the System VULNOFAST® Plus/VULNOLIGHT® In Addition To The Usual Care (UC) Vs UC Alone For The Treatment Of Infected Diabetic Foot Ulcers

Key facts

Who runs it
L.Molteni & C. dei F.lli Alitti-Soc. di Esercizio S.p.A.
Where
Italy7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
78 people enrolled
Started
14 Sept 2021
Ended
7 Apr 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Usual Care alone
  • System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care
Record updated
3 November 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Other criteria

  • Main Inclusion Criteria:
  • Able and willing to give voluntary written informed consent. The ICF, must be signed before any study-related procedures and/or assessments are performed
  • Outpatients or inpatients (male and female) of any ethnic origin, aged 18 years or over, diagnosed with type 1 or type 2 diabetes mellitus
  • Glycaemic control confirmed by a glycated haemoglobin (HbA1c) levels ≤10% (86 mmol/mol), evaluated in the 3 months before enrolment or at Visit 1
  • Fasting plasma glucose (FPG) less than 300 mg/dl
  • A chronic diabetic foot ulcer (DFU) below the malleolus, with an area ≥ 2 and ≤ 40 cm2 and with a maximum diameter/length ≤ 10 cm measured by MolecuLight i:X medical device [note: chronic wound is defined as a wound that, after the normal clinical practice, does not start healing within 4 weeks or does not heal within 8 weeks]
  • A diabetic foot wound with a depth equal or higher to grade 2 according to the category "Depth/tissue loss" of PEDIS, but not involving bone, diagnosed by clinical examination
  • Presence of infected foot ulcer of grade 2 according to the category "Infection" of PEDIS, diagnosed by clinical examination
  • Able to take oral medications
  • Patients must be willing and able to comply with the protocol and study procedures; Main Exclusion Criteria:
  • Patients unable to give written informed consent
  • Females who are pregnant or lactating
  • Females who are of child bearing potential and not taking adequate contraceptive precautions are excluded from the trial. Females of child bearing potential taking acceptable contraceptive precautions can be included
  • Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to Visit 1
  • Ankle brachial systolic blood pressure index < 0.5 (Winsor Index) in the infected limb
  • Ulcer probe to bone positive
  • Any surgery planned during the study period (from ICF signature to last planned follow-up visit)
  • Clinical diagnosis of peripheral vascular disease (PVD) requiring percutaneous or surgical revascularization
  • Transcutaneous oximetry (TcPo2) measurement < 30 mmHg
  • Use of any antibiotics (local or systemic) within 48h before Visit 1
  • Patient for whom punch biopsy is contraindicated
  • Patients that cannot take amoxicillin and clavulanic acid (background antibiotic therapy) at the dosage stated in the protocol and according to the current Summary of Product Characteristics (SPC)
  • Patients that cannot be treated with topical antiseptic containing Iodopovidone and/or with iodopovidone impregnated gauze according to the contraindication available in the current Summary of Product Characteristics (SPC)

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this randomised, open-label, multicentre clinical trial is to evaluate the superiority of the treatment which foresees the addition of the system VULNOFAST® plus / VULNOLIGHT® to the Usual Care, versus the treatment with Usual Care alone, for the healing of chronic diabetic foot ulcer. VULNOFAST® plus is a sterile solution used in combination with a red light source VULNOLIGHT®. Usual Care is defined as procedures to apply to the foot ulcer, carried out in the order in which they are listed in the protocol.

The 2 groups in the trial

  • Arm A: Usual Care aloneExisting treatment, for comparison

    Treatment: Usual Care alone

  • Arm B: system VULNOFAST® plus / VULNOLIGHT® in addition to Usual CareTreatment being tested

    Treatment: System VULNOFAST® plus / VULNOLIGHT® in addition to Usual Care

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomised, Open-Label, Multicentre Clinical Study To Evaluate The Efficacy And Safety Of Topical Applications Of the System VULNOFAST® Plus / VULNOLIGHT® In Addition To The Usual Care Versus Usual Care Alone For The Treatment Of Infected Foot Ulcers In Diabetic Patients (PHOTOFINISH)
Record updated
3 November 2026